

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

VOLUNTARY ANNOUNCEMENT

This announcement is made by WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**” or “**WuXi AppTec**”) on a voluntary basis.

The Company noted that there are recent media reports claiming that the Company is proposing to dispose its WuXi ATU business. As indicated in the Company’s response to media inquiry, the Company is currently assessing options for continuing WuXi ATU’s operations in line with our priorities: our employees and the patients who need essential, time-critical and life-saving treatments.

As at the date of this announcement, the Company has not formed any decisions on the above matter, and has not entered into any binding definitive agreements with any related parties. There is uncertainty as to whether the Company will eventually decide to dispose WuXi ATU, or take other options to retain WuXi ATU and execute other options so that such business can continue to operate. The Company will make further announcement (if any) as and when appropriate in accordance with applicable laws and regulations after there is a certain degree of certainty regarding the relevant matters.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, October 8, 2024

As of the date of this announcement, the Board comprises Dr. Ge Li, Dr. Minzhang Chen, Mr. Edward Hu, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Dai Feng as independent non-executive Directors.

* For identification purposes only